Xellia Pharmaceuticals USA LLC

Xellia Pharmaceuticals USA LLC is a pharmaceutical manufacturer and distributor that specializes in providing critical antibiotics and other medical supplies to the U.S. federal government, primarily through contracts with the Department of Defense and Department of Veterans Affairs. The company is registered to receive federal contract awards and has been active in government contracting since at least 2018. Xellia Pharmaceuticals USA LLC operates as a division of Xellia Pharmaceuticals, a global specialty pharmaceutical company focused on developing novel anti-infective therapies for serious and often life-threatening bacterial and fungal infections.

Through its federal contracts, Xellia Pharmaceuticals USA LLC primarily supplies intravenous vancomycin injections to the Defense Logistics Agency (DLA) Troop Support Medical. Vancomycin is a critical antibiotic used to treat serious bacterial infections in military medical facilities worldwide. The company has received numerous firm fixed price delivery orders for 1,000 mg vancomycin injections, with individual order values ranging from $42 to over $100,000. These orders are typically fulfilled from Xellia's manufacturing facility in Buffalo Grove, Illinois, with short turnaround times of just a few days between award and delivery dates. In addition to vancomycin, Xellia has also supplied other unspecified medical products to DLA Troop Support Medical. The majority of Xellia's federal contracts are awarded without set-aside designations, indicating the company competes for these opportunities on a full and open basis.

Xellia Pharmaceuticals USA LLC holds several significant indefinite delivery vehicle (IDV) contracts with the federal government. The largest is a $17,864,307.46 single award indefinite delivery/indefinite quantity (IDIQ) contract with DLA Troop Support Medical, awarded in September 2023, for various pharmaceutical products including vancomycin injections. This contract has a potential 10-year performance period through August 2033. Xellia also holds a $1,325,314.80 IDIQ contract with DLA for pharmaceutical distribution, awarded in December 2019 with a performance period through August 2023. Additionally, the company has a multiple award Federal Supply Schedule contract with the Department of Veterans Affairs, valued at up to $250,000, for drugs, pharmaceuticals, and hematology-related products. These IDV contracts serve as vehicles for Xellia to receive numerous delivery orders from defense and civilian agencies to supply critical medications and other medical supplies to support U.S. government healthcare programs.